Semaglutide: clinical trials recruiting now
43
Recruiting trials
15
Conditions studied
44
US states with sites
41
Countries
FDA drug label
- FDA-approved
- Yes. Semaglutide appears in the FDA drug-label database. Marketed as Ozempic.
- Drug class
- GLP-1 Receptor Agonist (FDA established pharmacologic class)
- Mechanism of action
- Glucagon-like Peptide-1 (GLP-1) Agonists (as stated on the FDA label)
- Boxed warning
- The FDA label for Semaglutide carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) • to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) • to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. ( 1 )
Phase breakdown
Phase 1 4
Phase 2 12
Phase 3 12
Phase 4 7
Not applicable 8
Conditions being studied
Recruiting trials involving Semaglutide
- A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
- A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
- A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
- A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
- A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
- A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- A Study of BGM0504 in Early T2DM With Obesity
- A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
- A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
- A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- COMMETS- Combination MCI Metabolic Syndrome
- Effect of Semaglutide in Patients With Psoriasis and Obesity
- Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
- Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
- Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
- Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
- GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity
- Impact of Semaglutide on Tobacco Use and Related Health Behaviors
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
- Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
- Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
- Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
- Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
- Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
- Probiotic Intervention on Body Weight
- Protein Supplementation Intervention on Body Weight
- Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
- Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
- Semaglutide for Smoking Cessation in Patients With Diabetes
- Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
- Sit Less, Interact and Move More (SLIMM) 2 Study
- Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin
- The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
- The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
- Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
- Weight Loss in Adults Using Semaglutide (Real-world Study)
Common questions
Is Semaglutide FDA-approved?
Yes, marketed as Ozempic. Its FDA label carries a boxed warning.
How many recruiting trials involve Semaglutide?
43 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.